Skip to content

Julia Lappin

6 papers in the library · 119 citations · publishing 2011-2026

Papers

Sort Most recent Most cited

The toxicology and characteristics of fatal new psychoactive stimulant and hallucinogen-related poisonings in Australia, 2000–2025

Drug and Alcohol Dependence Reports March 22, 2026 Shane Darke, Johan Duflou, Michael Farrell et al.

New psychoactive stimulants and hallucinogens (NPSH) poisonings have generated considerable public health concern in recent years. We aimed to determine: 1. The characteristics, toxicology and major autopsy findings of known cases of NBZD-related poisoning in Australia, 2000-2025; and 2. Changes in characteristics of known cases from 2020 onwards compared to earlier known cases. Retrospective...

DOI: 10.1016/j.dadr.2026.100434 (opens in new tab) Stimulant Poison control Psychoactive drug Toxicology +2

A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)‐ and psilocybin‐related death in Australia

Addiction May 21, 2024 Shane Darke, Johan Duflou, Amy Peacock et al. 14 citations

Abstract Background and aims Lysergic acid diethylamide (LSD) and psilocybin are used as recreational drugs, and there is renewed interest in their clinical use. The current study aimed to (1) determine the circumstances of death and case characteristics of LSD‐ and psilocybin‐related death in Australia, 2000–23; and (2) determine the toxicological profile and major autopsy findings of these...

Psychotogenic potential of prescribed drugs

Australian & New Zealand Journal of Psychiatry May 6, 2023 Julia Lappin, Shane Darke, Michael Farrell

Australian & New Zealand Journal of Psychiatry, 57(6) Interest in prescribing psychoactive drugs as treatments for mental health conditions has been highlighted recently by the decision by the Therapeutic Goods Administration (TGA) to permit, from 1 July 2023, authorised psychiatrists to prescribe medicines containing psilocybin for treatment-resistant depression and...

'Synthetic cannabis': A dangerous misnomer.

International Journal of Drug Policy December 1, 2021 Shane Darke, Samuel D Banister, Michael Farrell et al.

The term 'synthetic cannabis' has been widely used in public discourse to refer to a group of cannabinoid receptor agonists. In this paper we detail the characteristics of these drugs, and present the case that the term is a misnomer. We describe the pharmacodynamics of these drugs, their epidemiology, mechanisms of action, physiological effects and how these differ substantially from...

DOI: 10.1016/j.drugpo.2021.103396 (opens in new tab) Full text (opens in new tab) Cannabinoids Morbidity Synthetic cannabis Toxicity +1

MDMA-related deaths in Australia 2000 to 2018.

International Journal of Drug Policy December 19, 2019 A. Roxburgh, Julia Lappin 43 citations

BACKGROUND MDMA markets have undergone substantial changes internationally, with increasing manufacture of high purity MDMA recorded. This study examined trends in MDMA-related deaths in Australia, investigating characteristics, circumstances and toxicology of these deaths. METHODS Analysis of MDMA-related deaths in Australia between 2001 and 2018, extracted from the National Coronial...

History of cannabis use is not associated with alterations in striatal dopamine D 2 /D 3 receptor availability

Journal of Psychopharmacology September 2, 2011 Paul R A Stokes, Alice Egerton, Ben Watson et al. 62 citations

Cannabis use in adolescence is emerging as a risk factor for the development of psychosis. In animal studies, Δ9-tetrahydrocannabinol (THC), the psychoactive component of cannabis, modulates striatal dopaminergic neurotransmission. Alterations in human striatal dopaminergic function have also been reported both in psychosis and in stimulant use. We sought to examine whether striatal dopamine...

DOI: 10.1177/0269881111414090 (opens in new tab) Cannabis Raclopride Dopaminergic Striatum +3